Anakinra

Generic Name: Anakinra

Brand Names: Kineret

Drug Type: Biotech

Chemical Formula: -

CAS Number: 143090-92-0

Unique Ingredient Identifier: 9013DUQ28K

Background: Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...

Indication: Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)

Associated Therapies: -

Clinical Trials

CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection

Phase 2

Completed

Conditions: Corona Virus Infection

Interventions: Drug: Anakinra

First Posted Date: 2020-04-10

Last Posted Date: 2021-02-01

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 161

Registration Number: NCT04341584

Locations: 🇫🇷
Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France

Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction

Phase 2

Completed

Conditions: COVID-19
Virus Diseases
Macrophage Activation Syndrome
Corona Virus Infection

Interventions: Drug: Anakinra
Drug: Tocilizumab

First Posted Date: 2020-04-09

Last Posted Date: 2021-01-11

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 102

Registration Number: NCT04339712

Locations: 🇬🇷
Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece
🇬🇷
Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece
🇬🇷
Intensive Care Unit, "Latsio", Thriasio Elefsis General Hospital, Elefsína, Greece

and more 14 locations

Treatment of COVID-19 Patients With Anti-interleukin Drugs

Phase 3

Completed

Conditions: COVID-19

Interventions: Other: Usual Care
Drug: Anakinra
Drug: Siltuximab
Drug: Tocilizumab

First Posted Date: 2020-04-01

Last Posted Date: 2023-03-14

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 342

Registration Number: NCT04330638

Locations: 🇧🇪
University Hospital Antwerp, Edegem, Belgium
🇧🇪
Ziekenhuis Oost-Limurg, Genk, Belgium
🇧🇪
AZ Delta, Roeselare, Belgium

and more 12 locations

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Biological: CART-PSMA-TGFβRDN
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Anakinra

First Posted Date: 2020-01-13

Last Posted Date: 2023-08-21

Lead Sponsor: Tceleron Therapeutics, Inc.

Target Recruit Count: 16

Registration Number: NCT04227275

Locations: 🇺🇸
The University of Kansas Hospital, Kansas City, Kansas, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma
Progressive Disease
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma

Interventions: Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate

First Posted Date: 2019-12-20

Last Posted Date: 2024-12-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT04205838

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2

Active, not recruiting

Conditions: Neurotoxicity
Cytokine Release Syndrome
Refractory Non-Hodgkin Lymphoma
Relapsed Non Hodgkin Lymphoma
Non Hodgkin Lymphoma
Neurotoxicity Syndromes

Interventions: Drug: Anakinra
Drug: Axicabtagene Ciloleucel

First Posted Date: 2019-11-05

Last Posted Date: 2024-12-19

Lead Sponsor: Marcela V. Maus, M.D.,Ph.D.

Target Recruit Count: 15

Registration Number: NCT04150913

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Phase 2

Active, not recruiting

Conditions: B Cell ALL
B-Cell Lymphoma
B-cell Non Hodgkin Lymphoma

Interventions: Drug: Anakinra

First Posted Date: 2019-11-01

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 62

Registration Number: NCT04148430

Locations: 🇺🇸
Hackensack Meridian Health (Data collection only), Hackensack, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Placebos
Drug: Anakinra

First Posted Date: 2019-09-23

Last Posted Date: 2024-11-18

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 88

Registration Number: NCT04099901

Locations: 🇳🇱
University Medical Center Groningen (UMCG), Groningen, Netherlands
🇳🇱
Amsterdam UMC, location AMC, Amsterdam, Netherlands
🇳🇱
Radboudumc, Nijmegen, Netherlands